If you have been reading about IGF-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-26. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
In their 2019 Indian general election manifesto, the Bharatiya Janata Party (successor to the BJS) pledged its revocation. After its victory, the Parliament of India passed resolutions to repeal Article 370 in August 2019, and Article 35A was abolished through suspension of the 1954 Presidential Order. At the same time, a reorganisation act was also passed to reconstitute the state into two union territories: the new union territory of Ladakh, with the residual state continuing as the union territory of Jammu and Kashmir. The reorganisation took effect from 31 October 2019. In the days that followed, nearly 4,000 people, including two former Chief Ministers and hundreds of other politicians, were arrested by the Indian authorities in Kashmir; the state was put under a lockdown and communication and internet services were suspended. In April 2020, the government notified a domicile law to replace the previous 'permanent residents' scheme. Under the new law, any one that resided in Jammu and Kashmir for 15 years, or studied for seven years and appeared for Class 10 and Class 12 exams, would be deemed to be a 'domicile'. Government officials that served in Jammu and Kashmir for 10 years and their children also become eligible for domicile status. On 11 December 2023, the Supreme Court of India unanimously upheld the abrogation of Articles 370 and 35A, while also directing the union government to restore the statehood of Jammu and Kashmir and hold legislative assembly elections no later than September 2024. The assembly election was held from September to October 2024.
== Lithium carbonate equivalent == Lithium carbonate equivalent, abbreviated LCE, is an industry standard for lithium compounds whose lithium content is expressed in weight-equivalent of lithium carbonate. The term is commonly used in the lithium mining industry.
In September 2015, Holy Trinity Anglican Church was opened; the first church to be built in downtown Raleigh since 1958. On July 26, 2017, the Catholic Diocese of Raleigh dedicated its new cathedral, Holy Name of Jesus Cathedral, the fifth-largest in the United States. On October 13, 2022, a spree shooting occurred in Raleigh's Hedingham neighborhood. Five people were killed, and two others were injured. The suspect, a 15-year-old boy, was detained after being critically wounded and later remanded into the custody of the medical unit of a juvenile correctional facility.
Sources: en.wikipedia.org
The large POMC precursor is the source of numerous biologically active peptides, which are produced through sequential enzymatic cleavage. These include: N-Terminal Peptide of Proopiomelanocortin (NPP, or pro-γ-MSH) α-Melanotropin (α-Melanocyte-Stimulating Hormone, or α-MSH) β-Melanotropin (β-MSH) γ-Melanotropin (γ-MSH) 𝛿-Melanocyte-Stimulating Hormone (𝛿-MSH), found in sharks ε-Melanocyte-Stimulating Hormone (ε-MSH), present in some teleost fish Corticotropin (Adrenocorticotropic Hormone, or ACTH) Corticotropin-like Intermediate Peptide (CLIP) β-Lipotropin (β-LPH) Gamma Lipotropin (γ-LPH) β-Endorphin [Met]Enkephalin Although the first five amino acids of β-Endorphin are identical to [Met]enkephalin, β-Endorphin is not generally believed to be a precursor of [Met]enkephalin. Instead, [Met]enkephalin is produced independently from its own precursor, proenkephalin A. The production of β-MSH occurs in humans, but not in mice or rats, due to the absence of the necessary cleavage site in the rodent POMC sequence.
==== Fugitive, new sentences, and marriage ==== Olofsson escaped from the Norrköping prison on 20 March 1975. In April that year, he went into a bank in Copenhagen with a gun in each hand, fired a warning shot, and robbed the bank of SEK194,000. One month after the escape, Olofsson was in Marseille on the French Riviera. Together with a companion, he bought the sailboat Saga for 50,000 francs, and for three months they sailed around the Mediterranean. In August, they passed through the Strait of Gibraltar, out onto the Atlantic past the Azores. With the help of Inger and Mikael von Heijne from Djursholm, on their way home from the Caribbean, Olofsson got on the right course and finally reached Ireland. From there, they went to Denmark where Danish police came upon them. Olofsson escaped and it was not until January 1976 that the police caught up with him and managed to track him down at a crossroads outside Brussels. He managed to shoot himself free; on a train in Germany during this escape, he met 19-year-old Marijke Demuynck. On 24 March 1976, Olofsson robbed Handelsbanken on Östra Hamngatan 27 in Gothenburg of SEK 930,000 - at the time the largest robbery in Swedish criminal history. At the same time, he took two people hostage. He was arrested at 22:30, nine hours after the robbery, at hotel Gyllene Kärven in Herrljunga. SEK 230,000 was recovered during Olofsson‘s arrest; the rest was never found.
Gramicidin S or Gramicidin Soviet is an antibiotic that is effective against some gram-positive and gram-negative bacteria as well as some fungi. It is a derivative of gramicidin, produced by the gram-positive bacterium Brevibacillus brevis. Gramicidin S is a cyclodecapeptide, constructed as two identical pentapeptides joined head to tail, formally written as cyclo(-Val-Orn-Leu-D-Phe-Pro-)2. That is to say, it forms a ring structure composed of five different amino acids, each one used twice within the structure. Another interesting point is that it utilizes two amino acids uncommon in peptides: ornithine as well as the atypical stereoisomer of phenylalanine. It is synthesized by gramicidin S synthetase.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.